The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 May 2026•

1 min read

Gilead Sciences Q1 Earnings Beat Estimates on Strong Revenue Growth

Key Facts

1Gilead Sciences reported Q1 adjusted EPS of $2.03, surpassing analyst estimates of $1.91.

2The company's Q1 revenue reached $6.96 billion, beating the FactSet estimate of $6.91 billion.

3The company adjusted its 2026 adjusted loss per share range to $1.05-$0.65.

Gilead Sciences reported robust financial results for the first quarter, with both earnings and revenue exceeding analyst expectations. The company posted an adjusted EPS of $2.03, surpassing the consensus estimate of $1.91. Total revenue reached $6.96 billion, beating the $6.91 billion projected by FactSet analysts. Alongside the earnings beat, the company updated its long-term guidance, adjusting the 2026 adjusted loss per share range to between $1.05 and $0.65. This strong operational performance highlights the firm's resilience within the biotechnology sector. Investors are now assessing how these results and the updated guidance will influence the stock's trajectory in the coming quarters.